The added influence of genomics and post‐MRI confirmatory biopsy results to MRI results alone on medical decision making for men with favorable risk prostate cancer being considered for active surveillance-Reference-Cited by-同舟云学术

The added influence of genomics and post‐MRI confirmatory biopsy results to MRI results alone on medical decision making for men with favorable risk prostate cancer being considered for active surveillance

Published:2022-04-25 Issue:10 Volume:82 Page:1068-1074
ISSN:0270-4137
Container-title:The Prostate
language:en
Short-container-title:The Prostate

Author:

Wang Michael¹,Qi Ji²,George Arvin K.²,Semerjian Alice³,Linsell Susan M.²,Montie James E.²,Cher Michael L.¹,Ginsburg Kevin B.¹⁴^ORCID,

Affiliation:

1. Department of Urology Wayne State University Detroit Michigan USA

2. University of Michigan Medical School Ann Arbor Michigan USA

3. IHA Urology St. Joseph Mercy Hospital Ann Arbor Michigan USA

4. Department of Surgical Oncology, Division of Urologic Oncology Fox Chase Cancer Center Philadelphia Pennsylvania USA

Funder

Blue Cross Blue Shield of Michigan Foundation

Publisher

Wiley

Subject

Urology,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pros.24357

Reference20 articles.

1. Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

2. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

3. Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part I: risk stratification, shared decision making, and care options;Sanda MG;J Urol

4. Use of Active Surveillance or Watchful Waiting for Low-Risk Prostate Cancer and Management Trends Across Risk Groups in the United States, 2010-2015

5. Variation in the use of active surveillance for low-risk prostate cancer

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and Optimization of a Subtraction-Normalized Immunocyte Profiling Signature for Prostate Cancer Active Surveillance Risk Stratification;Journal of Urology;2023-12-26